Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas
AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against C...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 22; no. 36; pp. 8168 - 8177 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Inc
28.09.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 |
DOI | 10.3748/wjg.v22.i36.8168 |
Cover
Loading…
Abstract | AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients’ survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients’ age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients’ survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients’ survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC. |
---|---|
AbstractList | To investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival.
Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA II, CA VII, CA IX, and CA XII. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients' survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients' age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data.
CA II and CA XII staining intensities correlated with patients' survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA II intensity increased the hazard ratio to 1.19 fold (CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA XII staining intensity with survival of CRC patients (HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA XII immunostaining did not correlate to the patients' survival (P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA II staining was found. Increased extent of CA II had a significant hazard ratio among patients 65 years and older (1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA VII (intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA IX (intensity P = 0.879, extent P = 0.315, Kaplan-Meier analysis) immunostaining results and survival, or the other parameters.
The present findings indicate that CA II and CA XII could be useful in predicting survival in CRC. AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients’ survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients’ age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients’ survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients’ survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC. AIMTo investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival.METHODSColorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA II, CA VII, CA IX, and CA XII. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients' survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients' age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data.RESULTSCA II and CA XII staining intensities correlated with patients' survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA II intensity increased the hazard ratio to 1.19 fold (CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA XII staining intensity with survival of CRC patients (HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA XII immunostaining did not correlate to the patients' survival (P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA II staining was found. Increased extent of CA II had a significant hazard ratio among patients 65 years and older (1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA VII (intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA IX (intensity P = 0.879, extent P = 0.315, Kaplan-Meier analysis) immunostaining results and survival, or the other parameters.CONCLUSIONThe present findings indicate that CA II and CA XII could be useful in predicting survival in CRC. |
Author | Pia Viikil? Antti J Kivel? Harri Mustonen Selja Koskensalo Abdul Waheed William S Sly Jaromir Pastorek Silvia Pastorekova Seppo Parkkila Caj Haglund |
AuthorAffiliation | School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital;Department of Surgery, University of Helsinki and Helsinki University Hospital;Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine;Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences;Research Programs Unit, Translational Cancer Biology, University of Helsinki |
Author_xml | – sequence: 1 givenname: Pia surname: Viikilä fullname: Viikilä, Pia – sequence: 2 givenname: Antti J surname: Kivelä fullname: Kivelä, Antti J – sequence: 3 givenname: Harri surname: Mustonen fullname: Mustonen, Harri – sequence: 4 givenname: Selja surname: Koskensalo fullname: Koskensalo, Selja – sequence: 5 givenname: Abdul surname: Waheed fullname: Waheed, Abdul – sequence: 6 givenname: William S surname: Sly fullname: Sly, William S – sequence: 7 givenname: Edward A surname: Doisy fullname: Doisy, Edward A – sequence: 8 givenname: Jaromir surname: Pastorek fullname: Pastorek, Jaromir – sequence: 9 givenname: Silvia surname: Pastorekova fullname: Pastorekova, Silvia – sequence: 10 givenname: Seppo surname: Parkkila fullname: Parkkila, Seppo – sequence: 11 givenname: Caj surname: Haglund fullname: Haglund, Caj |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27688658$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UTtvFDEQtlAQuQR6KrQlBXvxc203SOjEI1KkNKS2vN7ZO0e7dmLvJTp6fggNQuJf8UvwkksEKZhiZqT5HtJ8R-ggxAAIvSR4ySRXJ7eX6-UNpUvPmqUijXqCFpQSXVPF8QFaEIxlrRmVh-go50uMKWOCPkOHVDZKNUIt0OnKpjYG7yobNrsu2QwVhC-7EXL16-u3N6V9n9uPcu_K_Fn5ULk4xARuskPlbHI-xNHm5-hpb4cML_bzGF18eP959ak-O_94unp3VjvO8VT3musWOgaE9a1qlOxbbB1njbWqhZ4rJlvegtSt0xJT7BrVdSA5iB4DU5wdo7d3ulfbdoTOQZiSHcxV8qNNOxOtN_9egt-YdbwxAjOJlSgCr_cCKV5vIU9m9NnBMNgAcZsNUVRQwjljBfrqb68Hk_v_FUBzB3Ap5pygN85PdvJxtvaDIdjMQZkSlClBmRKUmYMqRPyIeK_9HwrbUzYxrK99WD9wNFZzaYG54lpwQQT_s2H2G5wlqzk |
CitedBy_id | crossref_primary_10_1016_j_prp_2019_01_012 crossref_primary_10_1038_srep41191 crossref_primary_10_1080_14756366_2022_2085694 crossref_primary_10_1111_apm_12894 crossref_primary_10_1111_jbg_12541 crossref_primary_10_3389_fcell_2020_595969 crossref_primary_10_3389_fphar_2022_969422 crossref_primary_10_1016_j_semcancer_2022_01_001 crossref_primary_10_12998_wjcc_v9_i18_4520 crossref_primary_10_1186_s12866_023_02991_x crossref_primary_10_15252_embr_202050145 crossref_primary_10_1007_s00428_018_2424_z crossref_primary_10_1038_s41598_021_88133_7 crossref_primary_10_2217_bmm_2022_0071 crossref_primary_10_3892_ol_2019_10437 crossref_primary_10_1369_00221554211050133 crossref_primary_10_1016_j_bioorg_2018_08_005 crossref_primary_10_1016_j_intimp_2021_107830 crossref_primary_10_1002_open_202100042 crossref_primary_10_3390_cells13161311 crossref_primary_10_1186_s12864_023_09672_z crossref_primary_10_3892_mmr_2020_11047 crossref_primary_10_1038_s41598_024_76083_9 crossref_primary_10_1186_s12957_018_1432_4 crossref_primary_10_1007_s10620_021_06985_5 crossref_primary_10_1111_pin_12949 crossref_primary_10_3390_cimb46110774 crossref_primary_10_1080_13543776_2023_2245971 crossref_primary_10_1021_acs_analchem_3c04099 crossref_primary_10_3389_fonc_2022_871568 crossref_primary_10_1016_j_ejpb_2021_08_004 crossref_primary_10_1016_j_foodres_2023_113739 crossref_primary_10_1007_s13577_024_01125_3 crossref_primary_10_1111_jcmm_17027 crossref_primary_10_3390_ph16020188 crossref_primary_10_3390_ijms24032581 crossref_primary_10_1002_cam4_5562 crossref_primary_10_1016_j_gpb_2020_09_005 crossref_primary_10_1016_j_stem_2024_10_007 crossref_primary_10_1016_j_apradiso_2017_12_013 crossref_primary_10_1002_aoc_7882 crossref_primary_10_1142_S0192415X23500246 crossref_primary_10_1016_j_jcou_2020_101305 crossref_primary_10_1021_acs_jmedchem_3c01424 crossref_primary_10_3892_ol_2019_10242 |
Cites_doi | 10.1053/gast.1997.v112.pm9024293 10.1016/S0002-9440(10)65569-1 10.1158/1055-9965.EPI-07-0080 10.1200/JCO.2001.19.16.3660 10.1016/j.biochi.2010.05.008 10.3748/wjg.v11.i2.155 10.1136/bmj.321.7267.1004 10.1200/JCO.2005.00.471 10.1007/BF00268018 10.1038/nrc3579 10.1073/pnas.95.21.12596 10.1093/molehr/6.1.68 10.1016/j.cgh.2012.07.004 10.1136/gut.2003.036848 10.4236/health.2011.31002 10.3390/cancers3022767 10.2174/156802607780636690 10.1023/A:1011910931210 10.1136/bmj.321.7265.886 10.1038/nrd3554 10.1158/1055-9965.EPI-10-0437 10.1523/JNEUROSCI.5176-03.2004 10.4049/jimmunol.133.4.1710 10.1186/1471-2407-5-41 10.1038/nrc1478 10.1136/gut.35.5.646 10.1215/15228517-2007-001 10.1073/pnas.95.13.7608 10.1016/S0002-9440(10)64762-1 10.1038/modpathol.2009.189 10.1016/S0065-2423(06)42005-9 10.3748/wjg.v11.i17.2616 10.1158/0008-5472.CAN-03-2224 10.1136/bmj.321.7266.943 10.1002/med.10025 |
ContentType | Journal Article |
Copyright | The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016 |
Copyright_xml | – notice: The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016 |
DBID | 2RA 92L CQIGP ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.3748/wjg.v22.i36.8168 |
DatabaseName | 中文科技期刊数据库 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas |
EISSN | 2219-2840 |
EndPage | 8177 |
ExternalDocumentID | PMC5037085 27688658 10_3748_wjg_v22_i36_8168 90888889504849545154484950 |
Genre | Journal Article |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 WFFXF XSB ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c440t-f949bed3e13fb8687fb0ac436aa8bef4837b4be79bc97020c68dde74e5f0e3843 |
ISSN | 1007-9327 |
IngestDate | Thu Aug 21 18:14:56 EDT 2025 Fri Jul 11 02:20:47 EDT 2025 Thu Apr 03 07:05:55 EDT 2025 Tue Jul 01 02:11:28 EDT 2025 Thu Apr 24 22:58:56 EDT 2025 Wed Feb 14 10:15:14 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 36 |
Keywords | Immunohistochemistry Biomarker Prognosis Carbonic anhydrase Survival Colorectal cancer |
Language | English |
License | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c440t-f949bed3e13fb8687fb0ac436aa8bef4837b4be79bc97020c68dde74e5f0e3843 |
Notes | Pia Viikil?;Antti J Kivel?;Harri Mustonen;Selja Koskensalo;Abdul Waheed;William S Sly;Jaromir Pastorek;Silvia Pastorekova;Seppo Parkkila;Caj Haglund;School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital;Department of Surgery, University of Helsinki and Helsinki University Hospital;Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine;Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences;Research Programs Unit, Translational Cancer Biology, University of Helsinki ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Pia Viikilä, MD, School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital, Medisiinarinkatu 3, 33014 Tampere, Finland. viikila.pia.m@student.uta.fi Author contributions: Viikilä P, Parkkila S, Kivelä AJ and Haglund C participated in the design of the study; Clinical and survival data were collected by Koskensalo S and Haglund C; Haglund C collected samples of this study and constructed tissue microarrays; Immunohistochemical staining and light microscopy was performed by Viikilä P; Waheed A, Sly WS, Pastorek J, Pastorekova S and Parkkila S produced and characterized the primary antibodies; Statistical analysis was done by Mustonen H; Viikilä P drafted the first version of the manuscript; all authors were involved in the writing process, read, and approved the final manuscript. Telephone: +358-408-275235 Supported by the Sigrid Jusélius Foundation, the Academy of Finland, the Medical Research Funds of Tampere University Hospital and Helsinki University Hospital, and Jane and Aatos Erkko Foundation. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5037085 |
PMID | 27688658 |
PQID | 1825214433 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5037085 proquest_miscellaneous_1825214433 pubmed_primary_27688658 crossref_citationtrail_10_3748_wjg_v22_i36_8168 crossref_primary_10_3748_wjg_v22_i36_8168 chongqing_primary_90888889504849545154484950 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-09-28 |
PublicationDateYYYYMMDD | 2016-09-28 |
PublicationDate_xml | – month: 09 year: 2016 text: 2016-09-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2016 |
Publisher | Baishideng Publishing Group Inc |
Publisher_xml | – name: Baishideng Publishing Group Inc |
References | ref13 ref35 ref12 ref34 ref15 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 20647400 - Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907 8468192 - Histochemistry. 1993 Jan;99(1):37-41 11039973 - BMJ. 2000 Oct 21;321(7267):1004-6 16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28 10666387 - Am J Pathol. 2000 Feb;156(2):577-84 15836783 - BMC Cancer. 2005 Apr 18;5:41 9636197 - Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 17435181 - Neuro Oncol. 2007 Jul;9(3):308-13 15028762 - J Neurosci. 2004 Mar 17;24(11):2699-707 23969692 - Nat Rev Cancer. 2013 Sep;13(9):611-23 6206131 - J Immunol. 1984 Oct;133(4):1710-5 15633208 - World J Gastroenterol. 2005 Jan 14;11(2):155-63 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9 17504127 - Curr Top Med Chem. 2007;7(9):825-33 9665489 - Am J Pathol. 1998 Jul;153(1):279-85 11030689 - BMJ. 2000 Oct 14;321(7266):943-6 15710986 - Gut. 2005 Mar;54(3):374-84 11021873 - BMJ. 2000 Oct 7;321(7265):886-9 10611263 - Mol Hum Reprod. 2000 Jan;6(1):68-74 15849821 - World J Gastroenterol. 2005 May 7;11(17 ):2616-25 9770531 - Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 20493921 - Biochimie. 2010 Aug;92(8):1072-80 24212832 - Cancers (Basel). 2011 Jun 23;3(2):2767-810 20081808 - Mod Pathol. 2010 May;23(5):743-50 8200558 - Gut. 1994 May;35(5):646-50 9024293 - Gastroenterology. 1997 Feb;112(2):398-408 22835574 - Clin Gastroenterol Hepatol. 2012 Dec;10(12):1395-1401.e2 11504747 - J Clin Oncol. 2001 Aug 15;19(16):3660-8 11691824 - Cancer Res. 2001 Nov 1;61(21):7992-8 21921921 - Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77 12500287 - Med Res Rev. 2003 Mar;23(2):146-89 15342400 - Cancer Res. 2004 Sep 1;64(17 ):6160-5 11680594 - Dig Dis Sci. 2001 Oct;46(10 ):2179-86 17131627 - Adv Clin Chem. 2006;42:167-216 17855694 - Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1760-6 |
References_xml | – ident: ref24 doi: 10.1053/gast.1997.v112.pm9024293 – ident: ref18 doi: 10.1016/S0002-9440(10)65569-1 – ident: ref35 doi: 10.1158/1055-9965.EPI-07-0080 – ident: ref27 doi: 10.1200/JCO.2001.19.16.3660 – ident: ref23 doi: 10.1016/j.biochi.2010.05.008 – ident: ref9 doi: 10.3748/wjg.v11.i2.155 – ident: ref2 doi: 10.1136/bmj.321.7267.1004 – ident: ref6 doi: 10.1200/JCO.2005.00.471 – ident: ref22 doi: 10.1007/BF00268018 – ident: ref12 doi: 10.1038/nrc3579 – ident: ref21 doi: 10.1073/pnas.95.21.12596 – ident: ref25 doi: 10.1093/molehr/6.1.68 – ident: ref36 doi: 10.1016/j.cgh.2012.07.004 – ident: ref34 doi: 10.1136/gut.2003.036848 – ident: ref17 doi: 10.4236/health.2011.31002 – ident: ref5 doi: 10.3390/cancers3022767 – ident: ref10 doi: 10.2174/156802607780636690 – ident: ref32 doi: 10.1023/A:1011910931210 – ident: ref3 doi: 10.1136/bmj.321.7265.886 – ident: ref13 doi: 10.1038/nrd3554 – ident: ref1 doi: 10.1158/1055-9965.EPI-10-0437 – ident: ref16 doi: 10.1523/JNEUROSCI.5176-03.2004 – ident: ref7 doi: 10.4049/jimmunol.133.4.1710 – ident: ref28 – ident: ref33 doi: 10.1186/1471-2407-5-41 – ident: ref11 doi: 10.1038/nrc1478 – ident: ref14 doi: 10.1136/gut.35.5.646 – ident: ref29 doi: 10.1215/15228517-2007-001 – ident: ref31 doi: 10.1073/pnas.95.13.7608 – ident: ref20 doi: 10.1016/S0002-9440(10)64762-1 – ident: ref15 doi: 10.1038/modpathol.2009.189 – ident: ref26 doi: 10.1016/S0065-2423(06)42005-9 – ident: ref19 doi: 10.3748/wjg.v11.i17.2616 – ident: ref30 doi: 10.1158/0008-5472.CAN-03-2224 – ident: ref4 doi: 10.1136/bmj.321.7266.943 – ident: ref8 doi: 10.1002/med.10025 – reference: 11691824 - Cancer Res. 2001 Nov 1;61(21):7992-8 – reference: 8200558 - Gut. 1994 May;35(5):646-50 – reference: 15849821 - World J Gastroenterol. 2005 May 7;11(17 ):2616-25 – reference: 15028762 - J Neurosci. 2004 Mar 17;24(11):2699-707 – reference: 9024293 - Gastroenterology. 1997 Feb;112(2):398-408 – reference: 10611263 - Mol Hum Reprod. 2000 Jan;6(1):68-74 – reference: 8468192 - Histochemistry. 1993 Jan;99(1):37-41 – reference: 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9 – reference: 11030689 - BMJ. 2000 Oct 14;321(7266):943-6 – reference: 20081808 - Mod Pathol. 2010 May;23(5):743-50 – reference: 17504127 - Curr Top Med Chem. 2007;7(9):825-33 – reference: 15836783 - BMC Cancer. 2005 Apr 18;5:41 – reference: 20647400 - Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907 – reference: 15633208 - World J Gastroenterol. 2005 Jan 14;11(2):155-63 – reference: 9665489 - Am J Pathol. 1998 Jul;153(1):279-85 – reference: 12500287 - Med Res Rev. 2003 Mar;23(2):146-89 – reference: 11680594 - Dig Dis Sci. 2001 Oct;46(10 ):2179-86 – reference: 9636197 - Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 – reference: 15342400 - Cancer Res. 2004 Sep 1;64(17 ):6160-5 – reference: 22835574 - Clin Gastroenterol Hepatol. 2012 Dec;10(12):1395-1401.e2 – reference: 23969692 - Nat Rev Cancer. 2013 Sep;13(9):611-23 – reference: 17131627 - Adv Clin Chem. 2006;42:167-216 – reference: 11039973 - BMJ. 2000 Oct 21;321(7267):1004-6 – reference: 10666387 - Am J Pathol. 2000 Feb;156(2):577-84 – reference: 20493921 - Biochimie. 2010 Aug;92(8):1072-80 – reference: 21921921 - Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77 – reference: 17855694 - Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1760-6 – reference: 24212832 - Cancers (Basel). 2011 Jun 23;3(2):2767-810 – reference: 15710986 - Gut. 2005 Mar;54(3):374-84 – reference: 6206131 - J Immunol. 1984 Oct;133(4):1710-5 – reference: 16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28 – reference: 9770531 - Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 – reference: 11504747 - J Clin Oncol. 2001 Aug 15;19(16):3660-8 – reference: 11021873 - BMJ. 2000 Oct 7;321(7265):886-9 – reference: 17435181 - Neuro Oncol. 2007 Jul;9(3):308-13 |
SSID | ssj0023352 |
Score | 2.4174428 |
Snippet | AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS... To investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival. Colorectal... AIMTo investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients'... |
SourceID | pubmedcentral proquest pubmed crossref chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 8168 |
SubjectTerms | Aged anhydrase;Colorectal Antigens, Neoplasm - metabolism Basic Study Biomarker;Carbonic Biomarkers, Tumor - metabolism cancer;Immunohistochemistry;Prognosis;Survival Carbonic Anhydrase II - metabolism Carbonic Anhydrase IX - metabolism Carbonic Anhydrases - metabolism Colorectal Neoplasms - enzymology Colorectal Neoplasms - mortality Female Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Prognosis Proportional Hazards Models Regression Analysis Tissue Array Analysis Treatment Outcome |
Title | Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas |
URI | http://lib.cqvip.com/qk/84123X/201636/90888889504849545154484950.html https://www.ncbi.nlm.nih.gov/pubmed/27688658 https://www.proquest.com/docview/1825214433 https://pubmed.ncbi.nlm.nih.gov/PMC5037085 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa28bIXBOJWbgoSfkBeuyTOxXlsu1Zj0xDSNthbZCfOmi0ko2uHtnd-CC8IiX_FL-GcNEnbwSRGVbnxPfJ3enyOfXxMyGs_gmkziXhbxY7Zdnzut5UQCagqXhzpJHZ1hIri3jtv-9DZOXKPVlbXF6yWphPVia7-eq7kf1CFNMAVT8neAtmmUUiAZ8AXQkAYwn_CuC_HqrzBRuajy3gMExLT-dVl6X8JjRhc2rVwDOuItxgR5b5BHeux0iAdtHfggOgzBO8YyhvjoUp8pQOH9gQNPDrwaeBS0acDQQXHLz7YtGuWWT42OoB2t7DXgUeDLcyFlN4QcwdD2uvToFvW6tGeVZbxqPCxugioaExs36eSfUjT0zSjfIjODiYp22G7wKXLhG05Hqdsb4pCrEbel51Itlucn4J-LrOCdVU8zdhHOYJpuvZBwfbZfnbJduS4-JSOQYpGE1F9yvbT7AJ6q-PFhYT2zs4KhmfD4QUk68sT6PE4m-bx4nqJ5aFxh73I4nFxFqTW2TSvyzQb-DYUmjmOqiieL_J1vJ1kUUawZnfPXJ9_0JcPEM2Xk-POhW13Uu515jWXvHqjeRl8Ahc4KOiojotekfDJXCV3bFB57HrlqVo8wLNx5c599fazLXfscPN6d-gmZFTkx59B-FkWt_7Qoa6bAi_IVgf3yN1KKTK6Mwq_T1Z0_oC8ranbaKjbqKjb-PX12wYE3zH4Afkx_P400tyYU7Axp-CH5HA4OOhvt6uLP9qR45iTdhI4gdIx1xZPlPCEnyhTRg73pBRKJ3gJgnKU9gMVBT7oO5EnYJb2He0mpubC4Y_IWg5E94QYllbCkj6XyowcV4sg0bYplRXb2rR1bLfIRjNW4dnMwUt4MzgtslkPZxhVTvTxLpcsBGUawQgBjBDACAGMEMFokTdNjbr9m8u-qhEKgcvj1p3MdTE9Dy1hu-jckPMWeTxDrGnN9j0hQJFoEX8Jy6YAepBfzsnTUelJ3jW5DzrX09sNwjOyPv9jPSdrk_FUvwDRfKJeljT7G1AF0XA |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carbonic+anhydrase+enzymes+%E2%85%A1%2C+%E2%85%A6%2C+%E2%85%A8+and+%E2%85%AB+in+colorectal+carcinomas&rft.jtitle=%E4%B8%96%E7%95%8C%E8%83%83%E8%82%A0%E7%97%85%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Pia+Viikil%3F+Antti+J+Kivel%3F+Harri+Mustonen+Selja+Koskensalo+Abdul+Waheed+William+S+Sly+Jaromir+Pastorek+Silvia+Pastorekova+Seppo+Parkkila+Caj+Haglund&rft.date=2016-09-28&rft.issn=1007-9327&rft.eissn=2219-2840&rft.issue=36&rft.spage=8168&rft.epage=8177&rft_id=info:doi/10.3748%2Fwjg.v22.i36.8168&rft.externalDocID=90888889504849545154484950 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |